Eli Lilly and Company (NYSE:LLY)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for LLY
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- mopick: $LLY, at the 50d. Wary of this one, though.
- ReneeH: @mopick $LLY me too, been watching...actually looks a little bearish wedgey to me.
- camaro69: $LLY may be worth watching for a phase 3 move in the near future.
- ReneeH: @camaro69 $LLY been watching too...oddly potential for bearish wedge or maybe I'm seeing it more fearfully?
- camaro69: @ReneeH $LLY you're seeing it right! time will tell.
- marklesparkle: @ReneeH $LLY Plus Mr. 50d is sitting there along the trend line like @camaro says time will tell on this baby. Good eye good eye
- DavidG: @woodman $LLY $VKTX I like your comment that the oral drugs will be used for maintenance once weight loss is achieved with the parenteral forms. Also no physician who uses these has the high adverse reactions cited in the studies because we presccribe these at lower doses based on tolerance not on some artificial timetable dictated by study design.
- Henry: $LLY Up on news it's oral fat pill is moving forward
- woodman: @Henry $LLY - 10.5% weight loss in 72 weeks - a year and a half basically. Eh. $VKTX had 12.5% weight loss for its oral in 13 weeks. Subcutaneous remains the version that provides serious weight loss, though. Moreover, at the end of the day, I think it will come down to which of the drugs patients can tolerate and stay on. If you're throwing up, or can't have a BM, or have diharrea, and these can't be managed significantly, you're not going to stay on the drug for long.
- traderbren: $LLY - ugly chart, but pushing for a gap close on the upside to 740
- traderbren: $LLY - may be pushing for a gap fill up to 740
- camaro69: $LLY HOD
-
woodman: ...
All that said, the stock has been squashed back down to pre-run-up levels at the June low where it is now desperately battling to hold on. I could see it go even lower from here - today or in the following days. I make no predictions from here, thou ... - ReneeH: @woodman $VKTX $NVO $LLY it's a love hate here, when they move they move....both directions unfortunately. I feel ya.
- woodman: @ReneeH $VKTX $NVO $LLY - Trading vs investing, too. You can trade anything generally (though see below for biotech, specifically), but investing is a different thing. I think investing in small/mid cap biotech, particularly with no approved drugs, i ...
- ReneeH: @woodman $VKTX $NVO $LLY 100% agree, thank you. I'm much more of a trader vs investor. With biotech, I've had a few great hits and a lot of disappointment. Very tricky to time just right.
-
woodman: ...
Finally, as the review suggests, comparing VKTX's 12% weight loss at just 13 weeks vs. $LLY's oral version which achieved 11% at 72 weeks and $NVO's oral which achieved 14% at 64 weeks is - on its face - an unfair comparison. But they were Phase 3 d ... - joelsg1: @woodman $VKTX $LLY $NVO $LLY is preparing to flood the zone with their pill even before approval. I think it's a mistake to discount the no-needle convenience of the daily pill, but once massive supply is available, it's pretty much Game Over for the competitors, unless there's a huge difference in tolerability. And even on that last point, millions of people continue to take statins because they see immediate improvement in their cholesterol numbers, despite the fact that for many their feet, ankles, leg muscles hurt.
- woodman: @joelsg1 $VKTX $LLY $NVO - Funny thing is, I know many on the injectibles, and not one of them complains about it. It's such a nothing burger. At least not from a pain standpoint. But yes swallowing a pill is more convenient than dealing with syringes and vials or even autoinjectors.
- Bs7518: @woodman $VKTX $LLY $NVO Thanks for sharing the article I take the shot once a week and your right the pain is nothing so the pill is import to me but as an investor it is.
- mopick: $LLY, working it's way up to fill the gap, long
- woodman: $LLY https://finance.yahoo.com/news/eli-lilly-taps-high-grade-132106942.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAHqDnGToIGKiUcNfY-BtXgihmm7J6SAUNNT4j-yHm-9v-g5qDF6Uddo0Hyk2Tb6XYFWEnS62ElBo_5uEdGbz0S4ZtnddRzL33_MtNdgwU2TC5l63vfcWtkgVfw94rTnX-tcFcD8Daf-b0GWkcI8UkyTduyjqrpjLEwIWISe2y2NK
- camaro69: $LLY nearing HOD
-
woodman: ...
$VKTX - running up into oral obesity med data (expected 2H25 according to the company, but speculation is this or next month.) If the data are good, not just weight loss but, as expected, best in class tolerance/safety, it will be the best oral cand ... - traderbren: $LLY - pushing into upside gap. Not sure how much it can chew through as there's a ton of overhead supply.
- Vcondry: @traderbren $LLY i just got my $680 MS alert ... but im with you lots of overhead.
- DAN: @Vcondry $LLY Gap filling time!
- Vcondry: @DAN $LLY worth playing anything here?
- traderbren: $LLY - looks like they are trying to prop up the stock but it looks like there is more downside...in time. Eli Lilly & Co Insider Bought Shares Worth $1,052,263, According to a Recent SEC Filing
- woodman: $VKTX up again as the breakout/run into coming Phase 2 data (for the oral version of its obesity med) continues. I'm significantly long this one starting from ~$30. I suspect from past practice that the company will announce a date for it to provide ...
- ReneeH: @woodman $VKTX $LLY fantastic catch last week! watching for a long time, missed it but like it mucho. Thank you.
- woodman: @ReneeH $VKTX $LLY - Thanks. I started building in early-mid July, so it's been a bit of a wait and see.
- ReneeH: @woodman $VKTX $LLY tough spot here, but tempting. Data has been positive to date, higher quality than $HIMS, could do something "could" big
- woodman: @ReneeH $VKTX $LLY $HIMS - And bio, in general, is treacherous.
- billyzeke: $LLY's loss is $NVo's gain....there's a weight joke in there somewhere. I have no position in either.
- traderbren: @billyzeke $LLY $NVo - yeah, there probably is. Interesting to note that $NVO is up on the day while $LLY is tanking on the news. $NVO's pill performs better than $LLY.
- traderbren: $LLY - gap at 672.62
- woodman: $VKTX up on less than impressive $LLY oral weight loss med 72 week data. That said, I don't think this is what will cause a jail break for VKTX. The market is waiting for VKTX to report its own oral data, which folks seem to think will be reported this or next month. I am holding some VKTX for the data.
- wijimmy: $LLY getting slapped back to 2023 prices .. OVER REACTION… due to obesity pill results …. People on it only lost 12% of their body weight in one year of treatment…. which fell short of expectations, which WERE 15% of body weight. Worth watching IMHO
- Vcondry: @wijimmy $LLY 100% agree but no point in trying to be a hero...watching only for now.
- wijimmy: @Vcondry $LLY …. Ditto watching it in coming days like the.$AMZN and $SMCI trades
- bigreek42: $lly bouncing
- Geewhiz: $VKTX 11% pop on $LLY lack of good numbers on their oral obesity trials??
- woodman:
- woodman: @Geewhiz $VKTX $LLY - Correct. I've been holding shares for VKTX's coming oral data. I think it will come this or next month. I wouldn't mind seeing a run starting now on this lackluster LLY data.
- AndStars: @woodman @Bert953 The GLP-1 and GIP agonists are truly game changers. Not merely cosmetic. Truly improve the health directly by weight loss, but also in so many ways beyond mere weight loss. Cardiovascular disease. Diabetes. Depression. Anxiety. Kidney disease. OSA (obstructive sleep apnea). Peripheral neuropathy. To name a few. Besides increasing life span and quality of life, these drugs will be shown to save huge amounts on healthcare costs. Even at their high prices (which with time will come down) the cost vs. benefit is a no brainer. One reason why $LLY and $NVO can justify. Time for the health insurance industry ($UNH, et al) to get on board and cover this. It will reduce their costs by preventing expenditures on the above preventable disease states.
- woodman: @AndStars $LLY $NVO $UNH - I totally agree.
- joelsg1: $AMGN After $40 rise from triple bottom over past year, 3 day handle stopped at 20d intraday and reversed. Reports Monday Phase 2 results for weight loss drug Maritide at American Diabetes Assn., less frequent dosing and side effects compared with $LLY and others, up to bimonthly. Legacy long from way below, looking for bounce and collecting 3.2% divi.
- Henry: $VERV Gene editing, being bought by $LLY, trading above the buy out price of 10.50
- Dig44north: $LLY climbing the upper BB to take out the 200dma, macd curling up, on a nice run
- Dig44north: $LLY moving on Swedish drug deal, trying to regain the 50dma, full position
- makebackthemill: $LLY I am long this stock in my retirement portfolio. -- Forgetting the chart. It seems to me, a company that has invented the pill that will help people lose weight. (Pretty sure they passed their third trial) should be one of the greatest stocks of all time. Similar to the birth control company that invented the pill. Only LLY's pill can be USED by TWICE as many people. I just wanted to sound off about this because it drives me crazy that this stock isn't at least triple. Others are working on the pill, but are way behind. Any thoughts are welcome.
- woodman: @DavidK $SEPN $NVO - The weight-loss drug makers are looking for new molecules. $NVO is losing the GLP-1 battle to $LLY's Zepbound (current best in class). Orals are coming, as are new molecules. It's an ever-evolving area and new assets are needed. Companies mostly need to find them outside their own walls. $2 billion is inexpensive for these assets, if remotely promising. Many drug MFR CEOS want deals under $5 billion; under $3 billion even better.
- DavidK: @woodman $SEPN $NVO $LLY moving up into the close as I expected.
- woodman: @DavidK $LLY - It won't be every drug. Likely top Medicare drugs to be targeted. But no one - not even Pharma company management - knows right now.
- woodman: @DavidK $LLY - Moreover, if the plan is for the Administation to directly and unilaterally control drug prices by EO - also known as socialism, by the way - the courts will most likely strike it down as a clear separation of powers problem. This is the realm of Congress, not the President by EO. So, I'd say everyone should just cool their engines and wait to see what actually emerges from this on-going process. I can tell you, after speaking to a pricing guy I know in the Pharma industry, no one knows what this will end up being.
- joelsg1: @woodman $LLY Not sure what effect executive order has on price, except re direction to Oz at CMS for Medicare prices.
- Dig44north: @DavidK $LLY I would be careful with this ticker. One good announcement and this thing pops 10%.
- woodman: @DavidK $LLY - Something that could come from this, and it would be a good thing for consumers, IMO, is transparency in drug pricing and, particularly, exposing the drug pushers - $MCK $CAH, et al. - and get them to bring down their take. I say that even as I own some $MCK.
- DavidK: $LLY and all drug companies. Trump slamming the hammer on these crooks for the gouging . Any ideas on how / which company is best to short / buy puts .
- DavidK: @woodman $LLY $MCK $CAH the big issue being brought up is the exorbitant cost for the exact same drug in the USA as opposed to other countries . He mention Ozempic. which is a $NVO drug .
- woodman: @DavidK $LLY $MCK $CAH $NVO - Bringing down the price of GLP-1s would be a huge victory for consumers. The more testing they do and the more data that come in on them, the more they are finding these to be wonder drugs with so many benefits - not just weight loss itself. $LLY's Zepbound (aka Mounjaro for diabetes), which is superior to $NOV's Wegovy (aka Ozempic for diabetes) is currently $449 per month for private pay without insurance coverage for 5mg, which is on the low end of the dosing (it starts at 2.5mg, which is meant as a starter from which to move up) and goes to 15mg. Insurance doesn't cover it for the great majority of consumers.
- joelsg1: @woodman $LLY $MCK $CAH $NVO $NOV Interesting that now the GLP-1 stocks have reversed and moved higher. Maybe they know this executive order lacks teeth, or that they'll make it back with volume, $AMGN, $LLY and $HIMS.
- woodman: @woodman $LLY $MCK $CAH $NVO $NOV - EDIT: Zepbound is $499 (not $449) per month for the 5 mg dose via LillyDirect Self Pay Program.
- joelsg1: @woodman $LLY $MCK $CAH $NVO $NOV Or duct tape mouth when hungry, much cheaper :)
- woodman: @joelsg1 $LLY $MCK $CAH $NVO $NOV - For some, yes. For others, they simply can't lose the weight despite working out, maintaining good nutrition, and not over-eating. Plus, like I said, there are so many additional health benefits to taking the drug.
- Motorman: @woodman $ARVN $LLY too
- woodman: @Motorman $ARVN $LLY - I'm not good enough to focus on two of them at the same time. :-)
- Motorman: @woodman $ARVN $LLY Good point, I think I spread myself too thin.
- woodman: @Motorman $ARVN $LLY - I know my limitations. (At least I've convinced myself that I do.)
- traderbren: $LLY - nice money maker this morning - bought May 2 puts for the ride and closed on the 10 min candle at 797
- camaro69: @traderbren $LLY Nice ! I'm in at 796 for the bounce. we'll see if the selling is over
- traderbren: @camaro69 $LLY - yep, we could see a bounce trade...let's see if it can get above the VWAP.
- camaro69: @traderbren $LLY out of 75% now
- Henry: $LLY stock is trading higher on Thursday after the U.S. healthcare giant reported top line Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Eli Lilly adds that Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial.
- Onthemark: @Henry $LLY Doesn't hurt to have a small position as it could be a blockbuster. The old risk reward scenario.
- woodman: @Henry $LLY - LLY was able to slow titrate, which should help with tolerance. But the starting dose was low. $GPCR getting an even bigger bounce off the news. It has the same molecule, but safety/tolerance of GPCR's remains an unknown. There are doubts that the tolerance of its version will be good, particularly at high doses. $VKTX down on the LLY news, but it will provide 13 week data later this year and is expected to do even better in 13 weeks than what LLY just did in 40 weeks. I have no position in any of these stocks.
- Onthemark: @Onthemark $LLY Picked up some at 821.50 in the pre-market. Waiting for the stock to settle
- Wolf: #Big Pharma Only green I see other than $GLD. $MRK $JNJ $PJE $ABBV $LLY all up.
- Mikev200: $LLY HOD
- woodman: $HIMS - party may over for obesity drug compounders (though HIMS compounds drugs other than obesity drugs) with FDA's official announcement $NVO's Ozempic/Wegovy shortages (like $LLY's Zepbound/Mounjaro) are over, though I have a friend who said CVS told him there was some kind of problem filling his Zepbound prescription due to lack of supply, which is odd.
- joelsg1: $HIMS Losing weight as FDA lifts supply constraints on $NVO and $LLY weight loss drugs, Death knell for copycat compounders IMO. Might short any bounce.
- marklesparkle: @joelsg1 $HIMS $NVO $LLY Joel now that has a ring to it death knell for copycat compounders
- joelsg1: @marklesparkle $HIMS $NVO $LLY New punk band?
- woodman: @joelsg1 $HIMS $NVO $LLY - Good call.
- Dig44north: @joelsg1 $HIMS $NVO $LLY $LLY is strong, climbing the upper bb on the 5 min chart. Looking to take out my 900 cc
- woodman: @DavidG $VKTX - Lots of theories, because, you know, there's always a reason for a move, right? I don't know anything specifically attributed to this move that I'd call reliable. I saw some references to VK2735 and VK0214 trial recruitments/starts/co ...
- woodman: @woodman $VKTX $ALT $LLY $GPCR $HIMS $NVO - Just saw this. Cowen GLP-1 Market: The Pipeline Expands - Global GLP-1 sales in 2030 could reach $139B, up from our $101B forecast a little over a year ago. The market is maturing but accruing health outcomes data should broaden access and maintain momentum.
- woodman: @woodman $VKTX $ALT $LLY $GPCR $HIMS $NVO - Interesting that VKTX has dropped to a $3.8B market cap, and ended 2024 with a decent cash position of $903 million. But it is running multiple trials now, so it will have to burn a lot.
- debeers: $ANET-earnings tonight AMC $AXON-Amisure-- the earnings are 2/25 AMC keep this one $BP- bought it for nothing. Someone should scoop in and buy it 4/29earnings $GS-4/14 earnings. $INTC- i think it will be split in two and already 2 buyers $LLY-buy it when its down a bunch 5/1 earnings $NVDA- He's baaaack! 2/26 earnings $PLTR- yes he's out of his mind crazy but---and its a big butt- he delivers on government security 5/15 $T- you gotta have something that pays a divvie no matter what. this one's mine 4/23 earnings (who cares) $TPR-104 JPM target but by then they'll be reporting again. Shoes and handbgs. ITS IN THE BAG and if the shoe fits--buy it 5/8
- Dig44north: $LLY $COHR held $LLY thru the shake’n bake this morning after earnings, nice move. $COHR making a move after earnings, above all ma’s
- Dig44north: $LLY still on the ER run, 6 Feb bmo, holding thru with hedged upside cc
- Dig44north: $LLY nice mover last few days, trying to bust out of the upper BB, still below 100/200d. Watching
- Dig44north: $LLY is HOD, ER 6 Feb
- champ: $LLY is HOD, on #new-Guidance, about their #strong-growth on their obesity drugs, Mounjaro and Zepbound....and this move could continue zig-zagging higher into their earnings, on 2/6....I'm trailing, with room. ....Plus ....$JPM is having a Health Care conference and $LLY will be presenting on 2/14 and that could also be a positive game changer, on their #new-News about how strong their sales are. These are positive reasons for a short term Trading-position, that could turn into a long-term investing position.
- wijimmy: @wijimmy $LLY ..UGLY daily but if we zoom out its worth watching on weekly
- wijimmy: @vincenzo $LLY .. Wow, I can lose weight and stop snoring ... 2 for 1... I think most Insurance companies would pay for sleep apnea drug coverage before weight loss...could be BIG !!!! ... https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription
- traderbren: @Henry $NVO - agreed. It looks like $LLY is gaining weight as a result. ;-)
- traderbren: $LLY - phenomenal gap up this morning and pulled back to close the gap from this morning.
- smentor: @traderbren $LLY does this rally have any legs? Looks like it jumped up due to NVO not having good trial results.
| Stock Price | $1027.51 |
| Change | 1.80% |
| Volume | 3,272,640 |
Eli Lilly and Company is a drug manufacturing company. It discovers, develops, manufactures, and sells products in two business segments: human pharmaceutical products and animal health products.
Request Video of LLYAlready a member? Sign in here.
Past Month
Leading Peers
-
$14.74 43.93%
-
$5.87 31.12%
-
$6.95 23.22%
Past Month
Lagging Peers
-
$11.80 -19.70%
-
$40.15 -10.44%
-
$11.98 -8.63%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!